Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program - Montreal Gazette

Article Preview
Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass. -- Orthogon Therapeutics today announced
Preview provided under fair use. Full article available at original source.
Estimated reading time: 1 minute






